Dashboard
Manage Tickers

CRVS Corvus Pharmaceuticals, Inc.

Nasdaq corvuspharma.com


$ 7.05 $ -0.48 (-6.38 %)    

Friday, 17-Oct-2025 12:00:54 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 601.16 $ 3.51 (0.59 %)
DIA $ 461.31 $ 1.95 (0.42 %)
SPY $ 662.12 $ 2.65 (0.4 %)
TLT $ 91.15 $ -0.09 (-0.09 %)
GLD $ 390.30 $ -6.83 (-1.72 %)
$ 7.65
$ 7.62
$ 7.02 x 1
$ 7.05 x 46
$ 6.98 - $ 7.65
$ 2.54 - $ 10.00
1,401,784
na
570.03M
$ 1.16
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-25-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-06-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 03-19-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-08-2023 03-31-2023 10-Q
11 03-28-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 03-10-2022 12-31-2021 10-K
16 11-01-2021 09-30-2021 10-Q
17 08-02-2021 06-30-2021 10-Q
18 04-29-2021 03-31-2021 10-Q
19 03-25-2021 12-31-2020 10-K
20 10-29-2020 09-30-2020 10-Q
21 07-30-2020 06-30-2020 10-Q
22 04-30-2020 03-31-2020 10-Q
23 03-09-2020 12-31-2019 10-K
24 10-30-2019 09-30-2019 10-Q
25 08-01-2019 06-30-2019 10-Q
26 05-09-2019 03-31-2019 10-Q
27 03-07-2019 12-31-2018 10-K
28 11-01-2018 09-30-2018 10-Q
29 08-02-2018 06-30-2018 10-Q
30 05-03-2018 03-31-2018 10-Q
31 03-01-2018 12-31-2017 10-K
32 11-02-2017 09-30-2017 10-Q
33 08-03-2017 06-30-2017 10-Q
34 05-04-2017 03-31-2017 10-Q
35 03-10-2017 12-31-2016 10-K
36 11-03-2016 09-30-2016 10-Q
37 08-04-2016 06-30-2016 10-Q
38 05-05-2016 03-31-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

corvus-pharmaceuticals-presents-interim-data-from-the-phase-1b2-clinical-trial-of-ciforadenant-for-patients-with-metastatic-renal-cell-cancer-at-the-esmo-congress-2025-interim-data-shows-triplet-therapy-with-ciforadenant-ipilimumab-and-nivolumab-is-feasible-and-well-tolerated-longer-follow-up-with-patients-still-on-therapy-needed-to-determine-potential-benefit-of-blocking-adenosine-signaling
Corvus Pharmaceuticals Presents Interim Da...
10/17/2025 14:03:50

SOUTH SAN FRANCISCO, Calif.,, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage bi...

barclays-initiates-coverage-on-corvus-pharma-with-overweight-rating-announces-price-target-of-16
Barclays Initiates Coverage On Corvus Phar...
10/13/2025 12:04:19

Barclays analyst Etzer Darout initiates coverage on Corvus Pharma (NASDAQ:CRVS) with a Overweight rating and announces Price...

corvus-pharma-q2-eps-010-beats-013-estimate
Corvus Pharma Q2 EPS $(0.10) Beats $(0.13)...
08/07/2025 20:01:31

Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13)...

Core News & Articles
Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

corvus-says-partner-angel-pharmas-ind-approved-by-cde-of-china-nmpa-to-initiate-phase-1b2-clinical-trial-of-soquelitinib-for-treatment-atopic-dermatitis-in-china
Corvus Says Partner Angel Pharma's IND App...
06/25/2025 12:10:27

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the IND applicatio...

corvus-pharma-to-present-preclinical-data-highlighting-potential-of-soquelitinib-to-treat-systemic-sclerosis-at-eular-2025-congress
Corvus Pharma To Present Preclinical Data ...
06/11/2025 11:19:00

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced preclinical data highli...

corvus-pharma-announces-new-interim-data-from-randomized-double-blind-placebo-controlled-phase-1-clinical-trial-evaluating-soquelitinib-in-patients-with-moderate-to-severe-atopic-dermatitis
Corvus Pharma Announces New Interim Data F...
06/04/2025 11:07:10

Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2All three cohorts show separation from placebo with s...

mizuho-maintains-outperform-on-corvus-pharma-lowers-price-target-to-11
Mizuho Maintains Outperform on Corvus Phar...
05/20/2025 13:40:23

Mizuho analyst Graig Suvannavejh maintains Corvus Pharma (NASDAQ:CRVS) with a Outperform and lowers the price target from $1...

oppenheimer-reiterates-outperform-on-corvus-pharma-raises-price-target-to-17
Oppenheimer Reiterates Outperform on Corvu...
05/09/2025 17:20:20

Oppenheimer analyst Jeff Jones reiterates Corvus Pharma (NASDAQ:CRVS) with a Outperform and raises the price target from $15...

Core News & Articles
12 Health Care Stocks Moving In Friday's I...
05/09/2025 17:06:39

why-is-corvus-pharmaceuticals-stock-soaring-on-friday
Why Is Corvus Pharmaceuticals Stock Soarin...
05/09/2025 15:57:40

Corvus reported strong Phase 1 results for soquelitinib in atopic dermatitis, with early efficacy and no major safety concerns ...

Core News & Articles
12 Health Care Stocks Moving In Friday's P...
05/09/2025 12:10:06

why-pinterest-shares-are-trading-higher-by-13-here-are-20-stocks-moving-premarket
Why Pinterest Shares Are Trading Higher By...
05/09/2025 09:33:50

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
05/08/2025 21:05:48

corvus-pharma-q1-eps-013-misses-012-estimate
Corvus Pharma Q1 EPS $(0.13) Misses $(0.12...
05/08/2025 20:09:35

Corvus Pharma (NASDAQ:CRVS) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.1...

corvus-pharmaceuticals-announces-data-from-cohorts-1-3-of-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-in-patients-with-moderate-to-severe-atopic-dermatitis
Corvus Pharmaceuticals Announces Data From...
05/08/2025 20:03:47

Data continue to demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared...

Core News & Articles
Earnings Scheduled For May 8, 2025
05/08/2025 08:33:13

corvus-pharmaceuticals-announced-new-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis
Corvus Pharmaceuticals Announced New Inter...
04/23/2025 20:13:44

Data from Cohorts 1-3 of trial to be presented in an oral session and poster at the Society for Investigative Dermatology (SID)...

oppenheimer-maintains-outperform-on-corvus-pharma-raises-price-target-to-15
Oppenheimer Maintains Outperform on Corvus...
03/26/2025 17:00:50

Oppenheimer analyst Jeff Jones maintains Corvus Pharma (NASDAQ:CRVS) with a Outperform and raises the price target from $14 ...

hc-wainwright--co-reiterates-buy-on-corvus-pharma-maintains-11-price-target
HC Wainwright & Co. Reiterates Buy on Corv...
03/26/2025 10:26:30

HC Wainwright & Co. analyst Sean Lee reiterates Corvus Pharma (NASDAQ:CRVS) with a Buy and maintains $11 price target.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION